- Report
- May 2024
- 137 Pages
Global
From €6196EUR$6,499USD£5,291GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1907EUR$2,000USD£1,628GBP
- Report
- May 2024
- 133 Pages
Global
From €6196EUR$6,499USD£5,291GBP
- Clinical Trials
- April 2024
- 85 Pages
Global
From €1430EUR$1,500USD£1,221GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1192EUR$1,250USD£1,018GBP
- Report
- March 2024
- 200 Pages
Global
From €3957EUR$4,150USD£3,379GBP
- Report
- May 2023
- 200 Pages
Global
From €7151EUR$7,500USD£6,106GBP
- Report
- January 2022
- 200 Pages
Global
From €7151EUR$7,500USD£6,106GBP
- Report
- January 2022
- 60 Pages
Global
From €3766EUR$3,950USD£3,216GBP
- Report
- January 2022
- 60 Pages
Global
From €3766EUR$3,950USD£3,216GBP
- Drug Pipelines
- November 2020
- 251 Pages
Global
From €1907EUR$2,000USD£1,628GBP
- Report
- April 2023
- 96 Pages
Global
From €3500EUR$3,933USD£3,093GBP
- Report
- October 2022
- 106 Pages
Global
From €1907EUR$2,000USD£1,628GBP
- Report
- April 2021
- 55 Pages
Global
From €1907EUR$2,000USD£1,628GBP
Astrocytoma is a type of brain cancer that affects the astrocytes, a type of glial cell in the brain. Astrocytoma drugs are used to treat this type of cancer. These drugs are typically used in combination with surgery, radiation, and chemotherapy. Commonly used drugs include temozolomide, lomustine, and bevacizumab. These drugs are used to reduce tumor size, slow tumor growth, and reduce symptoms.
Astrocytoma drugs are typically administered orally or intravenously. Side effects of these drugs can include nausea, vomiting, hair loss, fatigue, and anemia. The cost of these drugs can vary depending on the type of drug and the dosage.
Some companies in the astrocytoma drug market include Merck, Novartis, Pfizer, and Roche. Show Less Read more
